Literature DB >> 28848143

PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.

Lujun Chen1,2,3,4, Yuqi Xiong1,2,3, Jing Li1,2,3, Xiao Zheng1,2,3, Qi Zhou1,2,3, Abbey Turner4, Changping Wu1,2,3, Binfeng Lu4, Jingting Jiang1,2,3.   

Abstract

BACKGROUND/AIMS: PD-L1 (Programmed cell death 1 ligand 1, PD-L1), an essential immune checkpoint molecule in the tumor microenvironment, is an important target for cancer immunotherapy. We have previously reported that its expression in human gastric and esophageal cancer tissues is significantly associated with cancer progression and patients' postoperative prognoses. Its expression in cancer cells is well known to inhibit the T cell-mediated anti-tumor response, and this mechanism of action has been targeted for cancer immunotherapy. As of now, the autonomous effect of PD-L1 on cancer cells is not well understood, thus our present study aimed to examine the role of PD-L1 intervention in cellular biological functions, especially epithelial to mesenchymal transition (EMT), of the human esophageal cancer cell line, Eca-109 cells.
METHODS: Immunohistochemistry assay was used to investigate the correlation between expression of PD-L1 and EMT markers in human esophageal cancer tissues. Intervention of PD-L1 by using RNAi and over-expression methods were used to study the role of PD-L1 in regulation of biological behaviors and EMT in Eca-109 cells.
RESULTS: Our clinical and pathological data demonstrated that tumor samples in the EMT positive subgroup had higher PD-L1 expression than those in the EMT negative subgroup. By manipulating PD-L1 expression in Eca-109 cells either through ablation or overexpression of wild type and the cytoplasmic domain-truncated mutant, we demonstrated that PD-L1 expression significantly promoted the cell viability, migration and EMT phenotype. Furthermore, our study also indicated that PD-1 fusion protein mediated stimulation of PD-L1 and the cytoplasmic domain of PD-L1 played a critical role in promoting EMT phenotype of Eca-109 cells, thereby suggesting that PD-1 receptor usually by triggering the reverse signaling can effect PD-L1 mediated regulation of esophageal cancer cell response.
CONCLUSION: Our present study reveals a tumor cell-autonomous role of PD-L1 signaling in promoting EMT in human esophageal cancer.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Epithelial to mesenchymal transition; Esophageal cancer; PD-L1

Mesh:

Substances:

Year:  2017        PMID: 28848143     DOI: 10.1159/000480000

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  43 in total

Review 1.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

2.  Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.

Authors:  Zhitao Dong; Boyi Liao; Weifeng Shen; Chengjun Sui; Jiamei Yang
Journal:  Dig Dis Sci       Date:  2019-08-13       Impact factor: 3.199

3.  Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.

Authors:  Reihaneh Alsadat Mahmoudian; Sahar Mozhgani; Mohammad Reza Abbaszadegan; Leila Mokhlessi; Mehdi Montazer; Mehran Gholamin
Journal:  J Mol Histol       Date:  2021-04-21       Impact factor: 2.611

4.  PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.

Authors:  Chunhua Chen; Shiheng Li; Junli Xue; Manlong Qi; Xin Liu; Yan Huang; Jinghua Hu; Haidong Dong; Kun Ling
Journal:  JCI Insight       Date:  2021-04-22

5.  The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer.

Authors:  Giuseppe Bronte; Maurizio Puccetti; Elisabetta Petracci; Lorenza Landi; Paola Cravero; Simona Scodes; Paola Ulivi; Sara Ravaioli; Maria Maddalena Tumedei; Marco Angelo Burgio; Federico Cappuzzo; Angelo Delmonte; Lucio Crinò; Sara Bravaccini
Journal:  Front Oncol       Date:  2021-05-04       Impact factor: 6.244

6.  Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.

Authors:  Ritu Shrestha; Prashanth Prithviraj; Kim R Bridle; Darrell H G Crawford; Aparna Jayachandran
Journal:  J Clin Med       Date:  2021-04-27       Impact factor: 4.241

Review 7.  Controversies around epithelial-mesenchymal plasticity in cancer metastasis.

Authors:  Elizabeth D Williams; Dingcheng Gao; Andrew Redfern; Erik W Thompson
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

Review 8.  Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.

Authors:  Iwona Kwiatkowska; Justyna Magdalena Hermanowicz; Alicja Przybyszewska-Podstawka; Dariusz Pawlak
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

9.  STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer.

Authors:  J Chen; Y Liu; Y Zhu; Y Chen; J Feng; T Jiang; X Zheng; L Chen; J Jiang
Journal:  Clin Transl Oncol       Date:  2022-02-02       Impact factor: 3.340

10.  TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas.

Authors:  Huanyu Zhang; Guohui Qin; Chaoqi Zhang; Huiyun Yang; Jinyan Liu; Hongwei Hu; Peng Wu; Shasha Liu; Li Yang; Xinfeng Chen; Xueke Zhao; Lidong Wang; Yi Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.